nach oben

23.04.2024 | Letter to the Editor

Dysautonomia and response to guanfacine in individuals with an SCN9A variant

verfasst von: Jose-Alberto Palma

Erschienen in: Clinical Autonomic Research

Einloggen, um Zugang zu erhalten

Excerpt

I read with interest the recent article by De Cassia Collaço et al., who reported two unrelated individuals with symptoms of anxiety and “dysautonomia” and experiencing a symptomatic response to 1 mg/day guanfacine [6]. The authors postulated that this response to what they considered a low dose of guanfacine was possibly due to a “particular genetic deficit” resulting in heightened sensitivity to the drug. Whole exome sequencing (WES) revealed a variant in the gene SCN9A (which encodes for the voltage-gated sodium channel Nav1.7) in both subjects. The authors concluded that this variant was responsible for the response to low-dose guanfacine and causally related to anxiety and “dysautonomia” in these individuals. …

Benarroch EE (2021) “Dysautonomia”: a plea for precision. Clin Auton Res 31:27–29CrossRefPubMed

Benjamin ER, Pruthi F, Olanrewaju S, Ilyin VI, Crumley G, Kutlina E, Valenzano KJ, Woodward RM (2006) State-dependent compound inhibition of Nav1. 2 sodium channels using the FLIPR Vm dye: on-target and off-target effects of diverse pharmacological agents. J Biomol Screen 11:29–39CrossRefPubMed

Biaggioni I, Shibao CA, Diedrich A, Muldowney JAS 3rd, Laffer CL, Jordan J (2019) Blood pressure management in afferent baroreflex failure: JACC review topic of the week. J Am Coll Cardiol 74:2939–2947CrossRefPubMedPubMedCentral

Darwin C (2005) The Expression of the Emotions in Man and Animals. Penguin Classics. London, England

Davidson JR, Foa EB, Connor KM, Churchill LE (2002) Hyperhidrosis in social anxiety disorder. Prog Neuropsychopharmacol Biol Psychiatry 26:1327–1331CrossRefPubMed

de Cassia CR, Lammens M, Blevins C, Rodgers K, Gurau A, Yamauchi S, Kim C, Forrester J, Liu E, Ha J, Mei Y, Boehm C, Wohler E, Sobreira N, Rowe PC, Valle D, Brock MV, Bosmans F (2024) Anxiety and dysautonomia symptoms in patients with a Na(V)1.7 mutation and the potential benefits of low-dose short-acting guanfacine. Clin Auton Res 34:191–201CrossRef

Dillon RC, Palma JA, Spalink CL, Altshuler D, Norcliffe-Kaufmann L, Fridman D, Papadopoulos J, Kaufmann H (2017) Dexmedetomidine for refractory adrenergic crisis in familial dysautonomia. Clin Auton Res 27:7–15CrossRefPubMed

Faber CG, Hoeijmakers JG, Ahn HS, Cheng X, Han C, Choi JS, Estacion M, Lauria G, Vanhoutte EK, Gerrits MM, Dib-Hajj S, Drenth JP, Waxman SG, Merkies IS (2012) Gain of function Nanu1.7 mutations in idiopathic small fiber neuropathy. Ann Neurol 71:26–39CrossRefPubMed

Han C, Hoeijmakers JG, Liu S, Gerrits MM, te Morsche RH, Lauria G, Dib-Hajj SD, Drenth JP, Faber CG, Merkies IS, Waxman SG (2012) Functional profiles of SCN9A variants in dorsal root ganglion neurons and superior cervical ganglion neurons correlate with autonomic symptoms in small fibre neuropathy. Brain 135:2613–2628CrossRefPubMed

10.

Jakala P, Riekkinen M, Sirvio J, Koivisto E, Kejonen K, Vanhanen M, Riekkinen P Jr (1999) Guanfacine, but not clonidine, improves planning and working memory performance in humans. Neuropsychopharmacology 20:460–470CrossRefPubMed

11.

Novak P, Systrom DM, Marciano SP, Knief A, Felsenstein D, Giannetti MP, Hamilton MJ, Nicoloro-SantaBarbara J, Saco TV, Castells M, Farhad K, Pilgrim DM, Mullally WJ (2024) Mismatch between subjective and objective dysautonomia. Sci Rep 14:2513CrossRefPubMedPubMedCentral

12.

Palma JA, Yadav R, Gao D, Norcliffe-Kaufmann L, Slaugenhaupt S, Kaufmann H (2021) Expanding the Genotypic Spectrum of Congenital Sensory and Autonomic Neuropathies Using Whole-Exome Sequencing. Neurol Genet 7:e568CrossRefPubMedPubMedCentral

13.

Pasierski M, Kolba W, Szulczyk B (2023) Guanfacine inhibits interictal epileptiform events and sodium currents in prefrontal cortex pyramidal neurons. Pharmacol Rep 75:331–341CrossRefPubMedPubMedCentral

14.

Sorkin EM, Heel RC (1986) Guanfacine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs 31:301–336CrossRefPubMed

15.

Suarez GA, Opfer-Gehrking TL, Offord KP, Atkinson EJ, O’Brien PC, Low PA (1999) The autonomic symptom profile: a new instrument to assess autonomic symptoms. Neurology 52:523–528CrossRefPubMed

Titel: Dysautonomia and response to guanfacine in individuals with an SCN9A variant
verfasst von: Jose-Alberto Palma
Publikationsdatum: 23.04.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: Clinical Autonomic Research
Print ISSN: 0959-9851
Elektronische ISSN: 1619-1560
DOI: https://doi.org/10.1007/s10286-024-01029-0

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Dysautonomia and response to guanfacine in individuals with an SCN9A variant

Excerpt

Neu in den Fachgebieten Neurologie und Psychiatrie

Schützt Olivenöl vor dem Tod durch Demenz?

Darf man die Behandlung eines Neonazis ablehnen?

Chirurginnen und Chirurgen sind stark suizidgefährdet

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu in den Fachgebieten Neurologie und Psychiatrie

Schützt Olivenöl vor dem Tod durch Demenz?

Darf man die Behandlung eines Neonazis ablehnen?

Chirurginnen und Chirurgen sind stark suizidgefährdet

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern